Atria Wealth Solutions Inc. Has $3.14 Million Position in Colgate-Palmolive (NYSE:CL)

Atria Wealth Solutions Inc. increased its position in shares of Colgate-Palmolive (NYSE:CL) by 1.3% during the fourth quarter, Holdings Channel reports. The institutional investor owned 39,394 shares of the company’s stock after purchasing an additional 500 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in Colgate-Palmolive were worth $3,140,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. &PARTNERS grew its stake in shares of Colgate-Palmolive by 0.7% in the fourth quarter. &PARTNERS now owns 17,643 shares of the company’s stock valued at $1,406,000 after buying an additional 129 shares in the last quarter. West Branch Capital LLC raised its holdings in shares of Colgate-Palmolive by 24.0% in the 4th quarter. West Branch Capital LLC now owns 682 shares of the company’s stock valued at $54,000 after purchasing an additional 132 shares during the period. First Foundation Advisors lifted its stake in Colgate-Palmolive by 2.7% in the 3rd quarter. First Foundation Advisors now owns 5,226 shares of the company’s stock valued at $372,000 after purchasing an additional 136 shares during the last quarter. Waldron Private Wealth LLC lifted its stake in Colgate-Palmolive by 2.7% in the 3rd quarter. Waldron Private Wealth LLC now owns 5,361 shares of the company’s stock valued at $381,000 after purchasing an additional 140 shares during the last quarter. Finally, Autumn Glory Partners LLC grew its holdings in Colgate-Palmolive by 2.7% during the fourth quarter. Autumn Glory Partners LLC now owns 5,319 shares of the company’s stock worth $424,000 after purchasing an additional 140 shares during the period. 80.41% of the stock is currently owned by institutional investors.

Colgate-Palmolive Stock Performance

Shares of NYSE:CL opened at $91.01 on Monday. Colgate-Palmolive has a 1 year low of $67.62 and a 1 year high of $92.25. The stock has a market capitalization of $74.81 billion, a price-to-earnings ratio of 28.80, a price-to-earnings-growth ratio of 3.42 and a beta of 0.42. The company has a debt-to-equity ratio of 8.59, a current ratio of 1.11 and a quick ratio of 0.71. The company’s 50 day simple moving average is $87.66 and its 200 day simple moving average is $81.63.

Colgate-Palmolive (NYSE:CL) last issued its earnings results on Friday, April 26th. The company reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.82 by $0.04. Colgate-Palmolive had a return on equity of 509.75% and a net margin of 11.82%. The firm had revenue of $5.07 billion for the quarter, compared to the consensus estimate of $4.96 billion. During the same quarter last year, the business posted $0.73 EPS. The company’s revenue was up 6.2% compared to the same quarter last year. As a group, research analysts predict that Colgate-Palmolive will post 3.5 EPS for the current fiscal year.

Colgate-Palmolive Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 15th. Shareholders of record on Monday, April 22nd will be paid a dividend of $0.50 per share. This is an increase from Colgate-Palmolive’s previous quarterly dividend of $0.48. The ex-dividend date is Friday, April 19th. This represents a $2.00 annualized dividend and a yield of 2.20%. Colgate-Palmolive’s payout ratio is presently 63.29%.

Insider Transactions at Colgate-Palmolive

In related news, EVP Gregory Malcolm sold 8,930 shares of Colgate-Palmolive stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $85.35, for a total transaction of $762,175.50. Following the sale, the executive vice president now directly owns 8,043 shares of the company’s stock, valued at approximately $686,470.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Noel R. Wallace sold 29,772 shares of the business’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $84.06, for a total transaction of $2,502,634.32. Following the sale, the chief executive officer now directly owns 301,343 shares in the company, valued at $25,330,892.58. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Gregory Malcolm sold 8,930 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $85.35, for a total transaction of $762,175.50. Following the completion of the transaction, the executive vice president now owns 8,043 shares of the company’s stock, valued at approximately $686,470.05. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 232,371 shares of company stock valued at $19,505,099. 0.34% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on CL. Stifel Nicolaus raised their price objective on Colgate-Palmolive from $89.00 to $94.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Morgan Stanley lifted their price objective on shares of Colgate-Palmolive from $85.00 to $93.00 and gave the stock an “overweight” rating in a research report on Monday, January 29th. The Goldman Sachs Group started coverage on shares of Colgate-Palmolive in a research report on Friday, March 1st. They issued a “buy” rating and a $93.00 price objective on the stock. JPMorgan Chase & Co. lifted their target price on shares of Colgate-Palmolive from $88.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, January 18th. Finally, TheStreet upgraded shares of Colgate-Palmolive from a “c+” rating to a “b+” rating in a research note on Friday, January 26th. Three equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $89.50.

Colgate-Palmolive Profile

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.